Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

6

US Previously Marketed

2

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Dopamine D1 receptor

6

Dopamine receptor

6

Androgen Receptor

2

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

8

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1960

2

1970

6

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Parkinson's disease

6

Anemia

2

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

8

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Active

8

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Hoffman-La Roche

6

Syntex

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

8

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

8

FDA UNII

8

PUBCHEM

8

SMS_ID

6

EPA CompTox

5

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

NERVOUS SYSTEM

3

ALIMENTARY TRACT AND METABOLISM

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTI-PARKINSON DRUGS

3

ANABOLIC AGENTS FOR SYSTEMIC USE

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

DOPAMINERGIC AGENTS

3

ANABOLIC STEROIDS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Dopa and dopa derivatives

3

Androstan derivatives

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

6

Principal Form

2

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 8 of 8 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

LEVODOPA

46627O600J

Export Data
Search for Structure

Status:

US Approved Rx (2019)

First approved in 1970

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Dopamine D1 receptor

Dopamine receptor

Conditions:

Parkinson's disease

Levodopa (L-DOPA) was first isolated from seedlings of Vicia faba by Marcus Guggenheim in 1913. Levodopa, a dopamine precursor, is an effective and well-tolerated dopamine replacement agent used to treat Parkinson's disease. Oral levodopa has been wi...

dely used for over 40 years, often in combination with a dopa-decarboxylase inhibitor carbidopa, which reduces many treatment complications, extending its half-life and increasing levodopa availability to the brain. Entacapone, a catechol-O-methyltransferase inhibitor, can also be used to improve the bioavailability of levodopa, especially when used in conjunction with a carbidopa.

17-HYDROXY-2-(HYDROXYMETHYLENE)-17-METHYLANDROSTAN-3-ONE, (2E,5.ALPHA.,17.BETA.)-

77LW93C64T

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1960

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Androgen Receptor

Conditions:

Oxymetholone (17beta-hydroxy-2-[hydroxymethylene]-17-methyl-5alpha-androstan-3-one) is a 17alpha-alkylated anabolic-androgenic steroid and a synthetic derivative of testosterone. It has been approved by the US Food and Drug Administration for the tre...

atment of anemias caused by deficient red cell production. Acquired aplastic anemia, congenital aplastic anemia, myelofibrosis and the hypoplastic anemias due to the administration of myelotoxic drugs often respond. Drug interactions exist with cimetidine, paroxetine, and haloperidol, but are not expected with indinavir, ritonavir, clarithromycin, or itraconazole.

BISMUTH SUBDOPATE

G69RN28K8B

Export Data
Search for Structure

Status:

US Approved Rx (2019)

First approved in 1970

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Dopamine D1 receptor

Dopamine receptor

Conditions:

Parkinson's disease

Levodopa (L-DOPA) was first isolated from seedlings of Vicia faba by Marcus Guggenheim in 1913. Levodopa, a dopamine precursor, is an effective and well-tolerated dopamine replacement agent used to treat Parkinson's disease. Oral levodopa has been wi...

dely used for over 40 years, often in combination with a dopa-decarboxylase inhibitor carbidopa, which reduces many treatment complications, extending its half-life and increasing levodopa availability to the brain. Entacapone, a catechol-O-methyltransferase inhibitor, can also be used to improve the bioavailability of levodopa, especially when used in conjunction with a carbidopa.

FOSLEVODOPA

37NQZ0J76I

Export Data
Search for Structure

Status:

US Approved Rx (2019)

First approved in 1970

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Dopamine D1 receptor

Dopamine receptor

Conditions:

Parkinson's disease

Levodopa (L-DOPA) was first isolated from seedlings of Vicia faba by Marcus Guggenheim in 1913. Levodopa, a dopamine precursor, is an effective and well-tolerated dopamine replacement agent used to treat Parkinson's disease. Oral levodopa has been wi...

dely used for over 40 years, often in combination with a dopa-decarboxylase inhibitor carbidopa, which reduces many treatment complications, extending its half-life and increasing levodopa availability to the brain. Entacapone, a catechol-O-methyltransferase inhibitor, can also be used to improve the bioavailability of levodopa, especially when used in conjunction with a carbidopa.

MELEVODOPA HYDROCHLORIDE

JFU1A8866V

Export Data
Search for Structure

Status:

US Approved Rx (2019)

First approved in 1970

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Dopamine D1 receptor

Dopamine receptor

Conditions:

Parkinson's disease

Levodopa (L-DOPA) was first isolated from seedlings of Vicia faba by Marcus Guggenheim in 1913. Levodopa, a dopamine precursor, is an effective and well-tolerated dopamine replacement agent used to treat Parkinson's disease. Oral levodopa has been wi...

dely used for over 40 years, often in combination with a dopa-decarboxylase inhibitor carbidopa, which reduces many treatment complications, extending its half-life and increasing levodopa availability to the brain. Entacapone, a catechol-O-methyltransferase inhibitor, can also be used to improve the bioavailability of levodopa, especially when used in conjunction with a carbidopa.

MELEVODOPA

M30686U4X4

Export Data
Search for Structure

Status:

US Approved Rx (2019)

First approved in 1970

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Dopamine D1 receptor

Dopamine receptor

Conditions:

Parkinson's disease

Levodopa (L-DOPA) was first isolated from seedlings of Vicia faba by Marcus Guggenheim in 1913. Levodopa, a dopamine precursor, is an effective and well-tolerated dopamine replacement agent used to treat Parkinson's disease. Oral levodopa has been wi...

dely used for over 40 years, often in combination with a dopa-decarboxylase inhibitor carbidopa, which reduces many treatment complications, extending its half-life and increasing levodopa availability to the brain. Entacapone, a catechol-O-methyltransferase inhibitor, can also be used to improve the bioavailability of levodopa, especially when used in conjunction with a carbidopa.

ETILEVODOPA

895X917GYE

Export Data
Search for Structure

Status:

US Approved Rx (2019)

First approved in 1970

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Dopamine D1 receptor

Dopamine receptor

Conditions:

Parkinson's disease

Levodopa (L-DOPA) was first isolated from seedlings of Vicia faba by Marcus Guggenheim in 1913. Levodopa, a dopamine precursor, is an effective and well-tolerated dopamine replacement agent used to treat Parkinson's disease. Oral levodopa has been wi...

dely used for over 40 years, often in combination with a dopa-decarboxylase inhibitor carbidopa, which reduces many treatment complications, extending its half-life and increasing levodopa availability to the brain. Entacapone, a catechol-O-methyltransferase inhibitor, can also be used to improve the bioavailability of levodopa, especially when used in conjunction with a carbidopa.

OXYMETHOLONE

L76T0ZCA8K

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1960

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Androgen Receptor

Conditions:

Oxymetholone (17beta-hydroxy-2-[hydroxymethylene]-17-methyl-5alpha-androstan-3-one) is a 17alpha-alkylated anabolic-androgenic steroid and a synthetic derivative of testosterone. It has been approved by the US Food and Drug Administration for the tre...

atment of anemias caused by deficient red cell production. Acquired aplastic anemia, congenital aplastic anemia, myelofibrosis and the hypoplastic anemias due to the administration of myelotoxic drugs often respond. Drug interactions exist with cimetidine, paroxetine, and haloperidol, but are not expected with indinavir, ritonavir, clarithromycin, or itraconazole.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1